A share price of Sionna Therapeutics Inc [SION] is currently trading at $15.84, up 6.81%. An important factor to consider is whether the stock is rising or falling in short-term value. The SION shares have gain 9.32% over the last week, with a monthly amount glided 24.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on March 04, 2025, and set its price target to $32. On March 04, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $45 on the stock.
Sionna Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $7.26 and $25.19. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Sionna Therapeutics Inc [NASDAQ: SION] shares were valued at $15.84 at the most recent close of the market. An investor can expect a potential return of 184.09% based on the average SION price forecast.
Analyzing the SION fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is 2.97 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.02 points at the first support level, and at 14.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.31, and for the 2nd resistance point, it is at 16.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sionna Therapeutics Inc [NASDAQ:SION] is 28.73. On the other hand, the Quick Ratio is 28.73, and the Cash Ratio is 8.68.
Transactions by insiders
Recent insider trading involved TPG GP A, LLC, 10% Owner, that happened on Feb 10 ’25 when 1.12 million shares were purchased. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Feb 10 ’25 to buy 1.12 million shares. Meanwhile, Director ORBIMED ADVISORS LLC bought 0.55 million shares on Feb 10 ’25.
